FDA’s Generic Priorities: McClellan Lays Out Ambitious Agenda At GPhA
This article was originally published in The Tan Sheet
Executive Summary
FDA is developing a process to flag NDAs that may pose difficulties for future generic development, Commissioner Mark McClellan, MD/PhD, said at the Generic Pharmaceutical Association annual meeting in Rio Grande, Puerto Rico Jan. 29